EUVIMEDEUVIMED entdecken
Crossref

The Predictive Value of Different Glasgow Prognostic Scores and the LabBM Score for Patients With Recurrent Glioblastoma

Dirk Rades, Oksana Zemskova, Jan Leppert, Nathan Y Yu

Anticancer Research · 2024

DOI: 10.21873/anticanres.17226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Dirk Rades und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Lübeck, Lübeck, Germany; dirk.rades@uksh.de. Hauptthemen laut MEDLINE: Glioblastoma, Neoplasm Recurrence, Local, Brain Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: The prognostic value of scoring instruments was described for newly diagnosed glioblastoma. This study investigated five instruments in patients with recurrent tumors. PATIENTS AND METHODS: Original Glasgow Prognostic Score (oGPS), modified GPS (mGPS), high-sensitivity mGPS (HS-mGPS), high-sensitivity oGPS (HS-oGPS), LabBM score, and 10 other factors were analyzed for progression-free survival (PFS) and overall survival (OS) in 51 patients. RESULTS: On univariate analyses, oGPS 0-1, mGPS 0-1, and LabBM score 0-1.0 were significantly associated with improved OS and showed trends for improved PFS. On multivariate analysis, a trend was found for associations between LabBM score 0-1.0 and better OS. In addition, maximal cumulative diameter ≤40 mm and systemic therapy were independently associated with better PFS and OS, resection with PFS, and in-field recurrence with OS. CONCLUSION: Lower oGPS, mGPS, and LabBM scores were significantly associated with improved OS on univariate analyses. These instruments may be helpful when designing personalized treatment regimens for patients with recurrent glioblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaNeoplasm Recurrence, LocalBrain NeoplasmsHumansFemaleMaleMiddle AgedPrognosisAgedAdultProgression-Free SurvivalPredictive Value of TestsAged, 80 and over

Stichwörter der Autor:innen

Glasgow Prognostic ScoreLabBM scoreRecurrent glioblastomaoverall survivalprogression-free survival

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Lübeck, Lübeck, Germany; dirk.rades@uksh.de.
  • Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.
  • Department of Radioneurosurgery, Romodanov Neurosurgery Institute, Kyiv, Ukraine.
  • Department of Neurosurgery, University of Lübeck, Lübeck, Germany.
  • Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, U.S.A.

Zitieren

APA

Rades, D., Zemskova, O., Leppert, J., & Yu, N. Y. (2024). The Predictive Value of Different Glasgow Prognostic Scores and the LabBM Score for Patients With Recurrent Glioblastoma. Anticancer Research. https://doi.org/10.21873/anticanres.17226

Vancouver

Rades D, Zemskova O, Leppert J, Yu NY. The Predictive Value of Different Glasgow Prognostic Scores and the LabBM Score for Patients With Recurrent Glioblastoma. Anticancer Research. 2024. doi:10.21873/anticanres.17226

BibTeX
@article{Rades2024,
  author = {Rades, Dirk and Zemskova, Oksana and Leppert, Jan and Yu, Nathan Y},
  title = {The Predictive Value of Different Glasgow Prognostic Scores and the LabBM Score for Patients With Recurrent Glioblastoma},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.17226}
}
Kostenlos starten →